Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Introduction: The identification of novel biomarkers associated with Alzheimer's disease (AD) could provide key biological insights and permit targeted preclinical prevention. We investigated circulating metabolites associated with incident dementia and AD using metabolomics. Methods: Plasma levels of 217 metabolites were assessed in 2067 dementia‐free Framingham Offspring Cohort participants (mean age = 55.9 ± 9.7 years; 52.4% women). We studied their associations with future dementia and AD risk in multivariate Cox models. Results: Ninety‐three participants developed incident dementia (mean follow‐up = 15.6 ± 5.2 years). Higher plasma anthranilic acid levels were associated with greater risk of dementia (hazard ratio [HR] = 1.40; 95% confidence interval [CI] = [1.15–1.70]; P = 8.08 × 10−4). Glutamic acid (HR = 1.38; 95% CI = [1.11–1.72]), taurine (HR = 0.74; 95% CI = [0.60–0.92]), and hypoxanthine (HR = 0.74; 95% CI = [0.60–0.92]) levels also showed suggestive associations with dementia risk. Discussion: We identified four biologically plausible, candidate plasma biomarkers for dementia. Association of anthranilic acid implicates the kynurenine pathway, which modulates glutamate excitotoxicity. The associations with hypoxanthine and taurine strengthen evidence that uric acid and taurine may be neuroprotective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 1×
“Given the expected complexity of AD and the relative success of agnostic genome-wide association studies, which suggested that additional biological pathways may modulate the risk of AD [10,11], a broader selection of circulating biomarkers might further improve our understanding of AD biology and risk prediction.”
BackgroundSelf-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“starting over 2 decades before clinical onset, so that intervention after the onset of clinical dementia is too late to prevent further progression [2,3].”
BackgroundPlasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011613 · Cited by 3,237
Self-citationMetabolite profiles and the risk of developing diabetes
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2307 · Cited by 3,143
Self-citationVillemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Epidemiological approaches to heart disease: the Framingham study
Dawber, T. R., Meadors, G. F., & Moore, F. E. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.3.279 · Cited by 2,148 · cited 7×
“The Framingham Heart Study (FHS) is an ongoing community-based prospective cohort study initiated in 1948 with the enrollment of 5209 women and men aged 28 to 74 years (Original Cohort) [15].”
InfluentialImmune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 1×
“Inflammation is now considered an important and early event in AD pathophysiology [41].”
BackgroundKynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Cited by
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia
Winchester, L. M., Harshfield, E. L., Shi, L., Badhwar, A., Khleifat, A. A., Clarke, N., Dehsarvi, A., Lengyel, I., Lourida, I., Madan, C. R., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13390 · Cited by 130
“45,46 A variety of potential biomarkers are studied in the context of disease riskpredictions,spanningneuropsychiatricandclinicalmeasurements, socioeconomic and lifestyle factors, neuroimaging, genetics and omics, as well as peripheral blood biomarkers.”
BackgroundYulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Lam, S., Velioglu, H. A., Yang, H., Coskun, E., Idil, E., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00336-2 · Cited by 79
“Accordingly, decreased levels of taurine and urea metabolites are associated with a diminished risk of dementia [131].”
BackgroundNeuffer, J., González-Domínguez, R., Lefèvre-Arbogast, S., Low, D. Y., Driollet, B., Helmer, C., Du Preez, A., de Lucia, C., Ruigrok, S. R., Altendorfer, B., et al. (2022) · Nutrients · doi:10.3390/nu14214688 · Cited by 40
Hurtado, M. O., Kohler, I., & de Lange, E. C. M. (2018) · Bioanalysis · doi:10.4155/bio-2018-0135 · Cited by 34
Metadata
- Authors
- Chouraki, V., Preis, S. R., Yang, Q., Beiser, A., Li, S., Larson, M. G., Weinstein, G., Wang, T. J., Gerszten, R. E., Vasan, R. S., & Seshadri, S.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-06-08
- Volume
- 13
- Issue
- 12
- Pages
- 1327-1336
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2623652145
- Cited by
- 126
- References
- 17
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study. https://app.cochat.ai/papers/10.1016/j.jalz.2017.04.009
- The paper
- Chouraki, V., Preis, S. R., Yang, Q., Beiser, A., Li, S., Larson, M. G., Weinstein, G., Wang, T. J., Gerszten, R. E., Vasan, R. S., & Seshadri, S. (2017). Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2017.04.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.